Trial Profile
Randomized controlled 12 months trial with etanercept (enbrel) vs. sulfasalazine followed by an open-label extension with etanercept up to week 540 in early axial spondyloarthritis with focus on improvement of acute inflammatory lesions as detected by MRI (ESTHER)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Etanercept (Primary) ; Sulfasalazine
- Indications Axial spondyloarthritis
- Focus Therapeutic Use
- Acronyms ESTHER
- 15 Mar 2021 Status changed from active, no longer recruiting to completed.
- 06 Jun 2020 Results presented at the 21st Annual Congress of the European League Against Rheumatism
- 06 Jun 2020 Results assessing 10-Year data of the etanercept versus sulfasalazin in early axial spondyloarthritis trial presented at the 21st Annual Congress of the European League Against Rheumatism